Answers are grounded in this paper and cite their sources.
Observational study reveals lower PD-L1 positivity rates in triple-negative breast cancer, suggesting important testing implications.
In this real-world study, PD-L1-positive prevalence was lower than in prospective trials assessing PD-L1 status centrally, lower in mTNBC than eTNBC, lower in smaller than larger tissue samples and lower by local than central assessment. These findings underline the importance of central PD-L1 testing on sufficiently large samples to ensure optimal selection for therapies targeting PD-(L)1 in mTNBC.
No takes yet. Share an insight, caveat, or question.
D'Arrigo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: